Phase I study of KRP-AM1977X (Clinical pharmacological study)

KRP-AM1977X Phase I Clinical Study -Examination of safety, pharmacokinetics and effects on gut microbiome after single and repeated oral administration in healthy adults-

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225163

Enrollment

Registered

2020-04-16

Start date

2011-10-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese healthy adult male subjects

Interventions

investigational material(s) Generic name etc : KRP-AM1977X INN of investigational material : lascufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for Invest

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Person with BMI that is more than 18.5 but less than 25.0, etc.

Exclusion criteria

Exclusion criteria: Drug allergy (including drug allergy to mydriatic agent), food allergy or atopy, and those who have a history of it

Design outcomes

Primary

Measure	Time frame
safety safety	—

Secondary

Measure	Time frame
pharmacokinetics pharmacokinetics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026